Endometrial cancer

This early-stage trial tests an experimental oral drug called CSCJC3456 in 102 people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any signs that the drug can shrink tumors. Participants take the table…

This study tests a new drug called ivonescimab in 50 people with advanced endometrial or cervical cancer that has worsened after standard chemotherapy. The drug targets two proteins (PD1 and VEGF) to help the immune system fight cancer and block tumor blood supply. Researchers wi…

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer or other solid tumors that have spread or cannot be removed. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 470 adults will tak…

This study tests whether a 24-week digital wellness platform, combined with one-on-one online sessions with a dietitian, exercise pro, and therapist, can help endometrial cancer survivors lose inches around their waist and improve their health. About 148 survivors who are overwei…

This study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…

This phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…

This Phase 3 trial tests whether the drug BNT323 (trastuzumab pamirtecan) works better than standard chemotherapy for people with recurrent endometrial cancer that expresses HER2. About 480 participants will be split into two groups based on their HER2 levels. The study measures …

This study tests whether adding sacituzumab tirumotecan (Sac-TMT) to pembrolizumab helps people with advanced or recurrent endometrial cancer live longer without the cancer getting worse. About 1,100 participants with a specific type of endometrial cancer (pMMR) will receive eith…

Researchers are testing a shorter, adapted form of radiation therapy for people with high-risk endometrial cancer after surgery. The trial enrolls 20 patients and uses daily imaging to adjust the radiation plan to each person's anatomy. Participants receive moderately hypofractio…

This early-phase study tests a new drug called BG-C9074, designed to target and kill cancer cells in people with advanced solid tumors that have not responded to standard treatments. The study will first find the safest dose, then test it alone or with other cancer drugs. About 3…

This study tests an experimental oral drug, GSK5460025, alone or with other cancer drugs, in adults whose solid tumors have specific genetic changes (dMMR or MSI-H). The goal is to see if the drug can shrink tumors and to check its safety. About 47 people with advanced cancers th…

This study tests whether two drugs, abemaciclib and letrozole, can help keep advanced or recurrent endometrial cancer from getting worse. About 32 people with a specific type of estrogen-sensitive cancer will take these pills daily after initial treatment. The goal is to see if t…

This phase II study is testing whether women with certain types of early-stage endometrial cancer can safely receive less aggressive treatment after surgery. The approach is guided by the tumor's molecular profile—either POLE-mutated or p53 wildtype/NSMP. Around 393 participants …

This study is testing whether the immunotherapy drug dostarlimab (TSR-042), followed by standard chemoradiation and surgery, can effectively treat advanced mismatch repair deficient (dMMR) solid tumors. About 212 adults with locally advanced dMMR cancers will receive the drug int…

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This early-phase trial tests SL-28, a cell therapy made from donor immune cells, in 60 people with advanced solid tumors (like lung, pancreatic, or breast cancer) that haven't responded to standard treatments. The study aims to find a safe dose and see if the therapy can shrink t…

This study tests a new drug called AZD8205, alone or with another drug (rilvegostomig), in people with advanced solid tumors like breast, ovarian, and lung cancers. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 460 adults whose c…

This study is testing a new drug called ubamatamab, given alone or with another drug called cemiplimab, in people with ovarian cancer or other cancers that have come back after treatment. The main goals are to check safety, find the right dose, and see if the drugs can shrink tum…

This early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…

This study tests whether tirzepatide, a drug used for weight loss and diabetes, can slow tumor growth in people with obesity-driven endometrial cancer. About 20 participants will take the drug before their scheduled hysterectomy. Researchers will compare cancer cell activity in t…

This Phase 1 trial tests a new drug called BL-M07D1 in 280 adults with advanced HER2-positive cancers, including breast, lung, and stomach cancers. The study aims to find safe doses and check for early signs of tumor shrinkage. Participants must have tried at least two prior trea…

This study compares a new drug called Rina-S to standard chemotherapy (paclitaxel or doxorubicin) in people with endometrial cancer that has returned or worsened after platinum-based chemo and immunotherapy. About 660 participants will be randomly assigned to receive either Rina-…

This study tests a new drug, LY4170156, designed to attack cancer cells with a specific marker (folate receptor alpha). It is for people with advanced solid tumors like ovarian, lung, or breast cancer that have not responded to other treatments. The trial has two parts: first fin…

This Phase III trial tests whether adding the drug bevacizumab to a standard chemotherapy plus immunotherapy regimen can help people with a specific type of advanced or recurrent endometrial cancer (pMMR, TP53 mutated). About 255 participants will be randomly assigned to one of t…

This Phase 2 trial tests an oral drug called BAY 2927088 (sevabertinib) in about 111 adults with advanced solid tumors that have HER2 gene mutations. The drug aims to block the abnormal HER2 protein and stop cancer growth. Participants take a 20 mg tablet daily in 3-week cycles u…

This phase 3 trial is testing whether a targeted drug (trastuzumab deruxtecan) combined with immunotherapy (rilvegostomig or pembrolizumab) works better than standard chemotherapy plus pembrolizumab for people with advanced or recurrent endometrial cancer that has a specific prot…

This early-stage trial is testing an investigational drug called ARR-002 in adults with advanced or metastatic ovarian or endometrial cancer, including cases that have stopped responding to platinum-based chemotherapy. The main goals are to assess the drug's safety, tolerability,…

This early-stage trial is testing a new drug called CTIM-76 in people with advanced ovarian, testicular, or endometrial cancers that have not responded to standard treatments. CTIM-76 is a bispecific antibody designed to attach to a protein called Claudin-6 on cancer cells and he…

This study is tracking the safety and effectiveness of durvalumab (with or without olaparib) in about 50 Korean patients with endometrial cancer who are already prescribed these drugs. Researchers will follow participants for up to 12 months to see how well the treatment works in…

This large Phase 3 study tests a new drug called mocertatug rezetecan (Mo-Rez) against standard chemotherapy for people with endometrial cancer that has progressed after platinum-based chemo and immunotherapy. About 600 participants will be randomly assigned to receive either Mo-…

This early-stage trial tests an experimental oral drug called NKT5097 in adults with advanced solid tumors, especially breast cancer. The drug works by breaking down two proteins that help cancer cells grow. Researchers want to find the safest dose and see if it can shrink tumors…

This early-phase study tests a new drug called STRO-004 in adults with advanced solid tumors that have not responded to standard treatments. The study has three parts: finding a safe dose of STRO-004 alone, testing that dose in more patients, and combining STRO-004 with another d…

This study tests two drugs, pembrolizumab and lenvatinib, in people with a type of uterine cancer that has come back after initial treatment. The cancer must be mismatch repair proficient, meaning it has a specific genetic feature. The goal is to see if this drug combination can …

This early-stage trial tests a daily oral drug called CGT6297 in 90 adults with advanced solid tumors that have a specific mutation in the PIK3CA gene. The study has two parts: first, finding a safe dose, and then looking for signs that the drug shrinks tumors. It focuses on peop…

This early-stage trial is testing a new drug called XmAb541 in people with advanced ovarian, endometrial, or germ cell tumors that have not responded to standard treatments. The main goal is to see if the drug is safe and to find the best dose. About 282 participants will receive…

This study is testing the drug T-DXd (Enhertu) in 100 adults with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. The goal is to see how well the drug works in real-world settings, including how many patients respond and …

This early-phase trial tests a new drug called STC-15, either alone or combined with an immunotherapy drug (toripalimab), in people with advanced solid tumors or certain sarcomas. The study aims to check safety and whether the drugs shrink tumors. About 107 participants will be e…

This trial is testing whether a shorter, more intense course of radiation therapy can be a safe and effective option for people with high-risk endometrial cancer after surgery. Instead of the usual weeks of daily radiation, the study uses just five sessions of a higher dose, guid…

This early-stage trial tests a new type of immunotherapy where a patient's own T cells are genetically engineered to recognize and attack cancer cells with a specific KRAS G12D mutation. The study includes adults with advanced lung, colorectal, pancreatic, or endometrial cancers …

This study tests a new drug called AZD5335, alone or with other cancer medicines, in people with advanced solid tumors like ovarian, lung, and endometrial cancers. The goal is to see if the drug is safe, tolerable, and shows signs of shrinking tumors. About 506 participants will …

This early-phase trial is testing an experimental biologic drug, DBC-664, in adults with advanced solid tumors such as ovarian, lung, and stomach cancers that have spread or come back. The study has two parts: first, finding a safe dose, and then expanding to see how well the dru…

This early-stage study tests a new drug called HH160 in about 56 adults with advanced solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will receive HH160 alone or with other cancer tr…

This study tests a new drug called BI 3820768 in adults with advanced germ cell tumors, endometrial cancer, or ovarian cancer who have run out of treatment options. The drug aims to help the immune system fight cancer. Researchers will give increasing doses to find a safe amount …

This Phase 2 trial tests an experimental drug called ACR-368, alone or with a low dose of gemcitabine, in 350 people with high-grade endometrial cancer. A special test (OncoSignature) helps decide which treatment arm a participant joins. The main goal is to see if the drug shrink…

This early-phase study tests a new drug, LNCB74, in people with advanced solid tumors (ovarian, breast, endometrial, bile duct, or lung cancer) that have not responded to standard treatments. The drug is designed to deliver a cancer-killing agent directly to tumor cells. The main…

This study tests an experimental drug called REGN5668, alone or combined with other drugs, in people with ovarian, fallopian tube, peritoneal, or endometrial cancer. The trial has two parts: first to find the safest dose, then to see if the drug shrinks tumors. About 612 particip…

This study is testing whether a shorter course of radiation therapy, given after surgery, can be as well-tolerated as the standard longer course for women with endometrial or cervical cancer. Instead of many small doses, the new approach uses five larger, precisely targeted doses…

This study tests an experimental drug called Tulmimetostat (DZR123) in people with advanced solid tumors or lymphomas that have not improved with standard treatments. The drug is taken as a daily pill, either alone or combined with another drug (enzalutamide) for certain prostate…

This early-phase study tests a new drug called HWK-016 in people with advanced ovarian or endometrial cancers that have not responded to other treatments. The drug is designed to deliver a toxic payload directly to cancer cells that carry a specific marker (MUC16). The main goals…

This early-phase trial is testing a new drug called NRM-823, alone or with immunotherapy, in people with advanced solid tumors like lung, ovarian, or breast cancer that haven't responded to standard treatments. The study aims to see if the drug is safe and tolerable. About 150 pa…

This early-phase study tests a new drug called GS-0201, given alone or with another cancer drug (sacituzumab govitecan), in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the best dose, and see how the body …

This study tests a combination of two drugs, sacituzumab govitecan and cisplatin, in people with ovarian or endometrial cancer that has come back but still responds to platinum-based treatments. The goal is to find the safest dose and see how well the drugs shrink tumors. About 5…

This phase 2 trial is testing a drug called datopotamab deruxtecan (Dato-DXd), alone or with other cancer medicines, in people with advanced or metastatic solid tumours. The study includes seven cancer types and aims to see if the drug shrinks tumours and how safe it is. Around 4…

This early-phase trial is testing a new drug called PHST001, which helps the immune system attack cancer cells by blocking a protein called CD24. The study will first test PHST001 alone, then in combination with standard chemotherapy, in adults with advanced solid tumors (includi…

This early-phase trial tests MGC026, a biologic drug given by IV, in 250 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. Participants receive u…

This trial is investigating whether combining an immunotherapy drug (a PD-1 inhibitor like sintilimab or pembrolizumab) with progesterone therapy can help young women with early-stage, mismatch repair-deficient (MMRd) endometrial cancer achieve complete remission while preserving…

This early-stage study tests a new drug called HWK-007 in people with advanced solid tumors, including certain ovarian, endometrial, and lung cancers. The drug is designed to target a protein (PTK7) found on cancer cells and deliver a chemotherapy-like payload directly to them. T…

This study tests a new drug, Rina-S, in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to see if Rina-S is safe and how well it works against cancers like ovarian, lung, and breast cancer. About 884 participants will receive the dru…

This early-stage trial tests an experimental drug called CTX-10726 in about 70 people with advanced gastroesophageal, liver, endometrial, or kidney cancers that have stopped responding to standard treatments. The main goal is to check safety and find the right dose. Participants …

This study tests an experimental drug called ART0380, taken as a pill, in people with advanced or metastatic solid tumors (cancers that have spread). The drug targets a protein that helps cancer cells repair their DNA. Researchers want to find the safest dose when given alone or …

This Phase 3 trial is testing a new drug called puxitatug samrotecan against standard chemotherapy in 800 people with advanced endometrial cancer that has worsened after platinum-based chemo and immunotherapy. The goal is to see if the new drug can delay cancer growth or improve …

This study is testing whether adding the immunotherapy drug camrelizumab to standard chemotherapy before surgery can help shrink advanced endometrial cancer. About 39 women with stage III or IV disease will receive the combination, then undergo surgery. The main goal is to see ho…

This phase 3 trial tests whether the targeted drug trastuzumab deruxtecan (T-DXd) works better than standard chemotherapy after surgery for HER2-positive endometrial cancer. About 710 adults with early-stage or locally advanced disease will be randomly assigned to receive T-DXd o…

This early-phase study tests a new drug called SLV-154 in about 70 people with advanced solid tumors (like head and neck, lung, breast, or ovarian cancer) that have spread. The main goal is to find a safe dose and check for side effects. Researchers will also watch for any signs …

This early-stage study tests a new oral drug, MOMA-341, alone or with other treatments, in people with advanced solid tumors that have specific genetic changes (MSI-H or dMMR). The main goal is to check safety and find the best dose. About 132 adults whose cancer has not responde…

This early-stage study tests a new drug called DAY301 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a powerful toxin directly to cancer cells while sparing healthy ones. The study aims to find the safest dose …

This early-phase trial is testing an experimental oral drug called RGT-490 in about 63 adults with advanced solid tumors (including certain breast, ovarian, and endometrial cancers) that have a PIK3CA gene mutation and have stopped responding to standard treatments. The main goal…

This early-stage study tests a new drug called PF-08046054/SGN-PDL1V, alone or with another drug (pembrolizumab), in people with advanced solid tumors like lung, head and neck, esophageal, breast, stomach, endometrial, pancreatic, or liver cancer. The main goals are to find safe …

This trial tests whether a 3-day low-residue diet can replace a rectal enema for bowel preparation before laparoscopic endometrial cancer surgery. One hundred women scheduled for surgery will be randomly assigned to either the diet or an enema. The study measures how well the sur…

This early-phase trial tests a wearable device that creates electric fields (tumor treating fields) combined with either cabozantinib or nab-paclitaxel and atezolizumab in 43 people with advanced solid tumors in the abdomen or chest. The goal is to find the safest dose and see if…

This study tests if the drug elacestrant, alone or with abemaciclib, can shrink or control advanced or recurrent ER+ endometrial cancer. About 75 adults who have already had chemotherapy and immunotherapy will take part. The goal is to see how well the treatment works and if it i…

This study tests a drug called relacorilant, taken as a pill, combined with two standard chemotherapy drugs (nab-paclitaxel and bevacizumab) in people with ovarian, fallopian tube, peritoneal, or endometrial cancers. The goal is to see if the combination can slow cancer growth or…

This study tests a drug called enfortumab vedotin in up to 12 people with advanced endometrial (uterine) cancer that has worsened after standard treatments like immunotherapy. The drug works by targeting a protein on cancer cells to kill them. Researchers will measure how many pa…

This study looks at whether a simple blood test (ctDNA) can help doctors decide if it's safe to stop maintenance immunotherapy after one year in people with advanced or recurrent endometrial cancer. About 30 participants will receive standard treatment, and if their ctDNA test is…

This phase 2 trial tests a drug called zanidatamab in about 200 adults with advanced HER2-positive cancers, including breast, lung, stomach, and others. Participants have already tried at least one standard treatment. The study measures how many tumors shrink or disappear. Zanida…

This study is for women with a certain type of endometrial cancer (called MMR-D/MSI-H) who have already had surgery. It tests whether adding radiation and an immunotherapy drug called dostarlimab can help keep the cancer from coming back. About 62 participants will receive the co…

This study tests a new drug called mocertatug rezetecan (Mo-Rez) combined with other cancer medicines for people with advanced solid tumors that have stopped responding to standard treatments. About 305 adults will join to see if the combination is safe, tolerable, and effective.…

This early-phase study tests a new drug called XMT-1660 in about 319 people with advanced solid tumors, including breast, ovarian, and endometrial cancers. The main goals are to find the safest dose and check for side effects. Researchers will also see if the drug shrinks tumors.…

This early-phase study tests a combination of three drugs (avutometinib, defactinib, and everolimus) in people with recurrent endometrial cancer that has specific genetic changes in the RAS pathway. The main goal is to find a safe dose and understand side effects. About 31 partic…

This phase 2 trial tests a drug called mirvetuximab soravtansine in 50 women with a specific type of endometrial cancer that has come back or won't go away. The drug targets a protein called folate receptor alpha, which is often found on these cancer cells. Researchers want to se…

This study tests a new drug called XTX301 in people with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and then testing that dose in specific cancer types. Researchers will monitor side effects and wheth…

This early-phase study tests whether a short course of radiation (1 week instead of the usual 5) combined with standard chemotherapy (carboplatin and paclitaxel) is practical for people with stage III endometrial cancer. The trial will enroll 28 participants and aims to see if mo…

This early-stage trial tests an experimental drug called mocertatug rezetecan in 675 adults with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The main goals are to check safety, find the ri…

This study is collecting real-world data from 150 women in Germany with advanced or recurrent endometrial cancer. Participants receive standard first-line treatment with chemotherapy plus durvalumab, followed by maintenance therapy with durvalumab alone or with olaparib. The goal…

This early-stage trial tests a new drug called LY4175408, which is designed to seek out and attack cancer cells that have a specific marker (PTK7). The study includes 240 people with advanced lung, endometrial, or triple-negative breast cancers that have not responded to standard…

This phase 2 trial tests whether combining hormone therapy (letrozole) with a targeted drug (abemaciclib), and possibly adding metformin or gedatolisib, can control estrogen-receptor-positive endometrial cancer that has returned or spread. The study enrolls adults with this cance…

This early-phase study is testing an experimental drug called IDE034 in 150 adults with advanced solid tumors (such as lung, ovarian, or colorectal cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see …

This study tests a new drug called INV-8989 in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The trial has two phases: the first finds the safest dose, and the second checks how well the drug shrinks tumors. About 178 adults with cancers …

This early-stage trial is testing whether combining chemotherapy and radiation, followed by more chemotherapy plus the immunotherapy drug dostarlimab, is safe and tolerable for people with stage IIIC node-positive endometrial cancer. The study aims to see if this approach can hel…

This study tests a new drug called MORAb-202 that targets a protein (folate receptor alpha) found on some cancer cells. It is for people with ovarian, endometrial, non-small cell lung, or triple-negative breast cancer. The trial has two parts: first to find the safest dose, then …

This phase 2 trial tests whether a combination of a gonadotropin-releasing hormone agonist (triptorelin) and letrozole can achieve better complete response rates than standard hormone therapy (megestrol acetate or medroxyprogesterone acetate) in women with early-stage endometrial…

This study tests a combination of an immune-boosting drug (TQB2450) and a high-dose hormone (progestin) to treat young women (ages 18-45) with a specific type of early-stage endometrial cancer (MMRd). The goal is to eliminate the cancer while preserving the uterus so patients can…

This study compares a new barbed suture (SYMMCORA) with a standard one (V-Loc) for closing the vaginal cuff after laparoscopic hysterectomy. The goal is to see if the new suture reduces stitching time without increasing complications. About 132 women having elective laparoscopic …

This phase 2 trial is testing a drug called lorigerlimab in about 80 people with advanced ovarian or clear cell gynecologic cancers that have stopped responding to platinum chemotherapy. Lorigerlimab is a bispecific antibody designed to activate the immune system against tumors. …

This phase 2 trial is testing two immunotherapy drugs, durvalumab and tremelimumab, alone or together, in 60 people with colorectal or endometrial cancer. The goal is to see if these drugs can shrink tumors or slow cancer growth. The study focuses on patients with different genet…

This study tests an experimental drug called INV-6452 in adults with advanced breast cancer (HR+/HER2-) or other solid tumors that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 201 participants wil…

This study tests a new drug called ifinatamab deruxtecan in people with advanced solid tumors that have not been cured by other treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 250 participants will take part, and those who benefit may …

This study tests a new drug called BC3195 combined with pembrolizumab (an immunotherapy) in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if the combination can shrink tumors. About 111 adults with certain cancers will take part.

This study tests new treatments for endometrial cancer based on the genetic makeup of each person's tumor. About 1,615 participants will be assigned to one of four trials depending on their cancer's molecular profile. The goal is to see if these tailored therapies can prevent the…

This study tests a new drug called MDX2001 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety and see if it can shrink tumors. About 285 adults with various cancers like lung, breast, or colon cancer will take part. This is an ear…

This study tests a combination of two drugs, cabozantinib and dostarlimab, in 37 women with recurrent gynecologic carcinosarcoma, a rare and aggressive cancer. The goal is to see if the combo can keep the cancer from growing for at least 6 months. Participants must have had at le…

This early-stage trial is testing a new drug called TGW101 in people with advanced solid tumors that have not responded to other treatments. TGW101 is given in two parts: an antibody-drug conjugate and a chemical trigger that activates it. The main goal is to check safety and fin…

This early-stage trial tests a new drug called KIVU-107 in 76 adults with advanced solid tumors that have not responded to standard treatments. KIVU-107 is an antibody-drug conjugate designed to target and kill cancer cells. The main goal is to find a safe dose and check for side…

This study tests a new drug called EIK1005, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if the drug shrinks tumors. About 160 adults with certain cancer types…

This study tests a personalized vaccine plus three other drugs in 60 adults with advanced HER2-positive endometrial cancer that returned after treatment. The vaccine is made from each patient's own blood cells and targets the HER2 protein. The goal is to see if this combination c…

This early-stage trial is testing an experimental drug called MOv18 IgE in people with advanced ovarian, endometrial, or triple-negative breast cancers that have a specific protein (folate receptor alpha) on their cells. The study has two parts: first, finding the safest dose, an…

This study tests whether combining targeted drugs with the immunotherapy atezolizumab can shrink tumors or slow cancer growth in people with endometrial cancer that has come back or persists. About 148 participants whose cancer has progressed after at least one prior treatment wi…

This study tests whether injecting a lab-made collagen into the uterus, along with daily hormone pills, can help shrink early-stage endometrial cancer or precancerous growths. The goal is to preserve fertility in women aged 45 or younger. Thirty participants will either receive t…

This early-phase study tests a new drug called 177LuBetaBart in people with advanced solid tumors that have stopped responding to standard treatments. The drug is a radioactive antibody designed to seek out and destroy cancer cells. The study will enroll about 61 participants and…

This early-stage trial is testing a new daily oral medication called ETX-19477 in about 120 adults with advanced solid tumors, including breast, ovarian, prostate, and other cancers. The drug blocks a protein called PARG to interfere with cancer cells' ability to repair themselve…

This study tests two drugs, envafolimab (an immunotherapy) and lenvatinib (a targeted therapy), alone or together, in 108 people with advanced endometrial cancer that has worsened after standard chemotherapy. The main goal is to see if the drugs shrink tumors. Researchers will al…

This study aims to improve fertility-sparing treatment for young women (ages 18-45) with endometrial cancer by tailoring therapy to the tumor's genetic profile. Participants will receive either hormone therapy (progestins) or a combination with an immunotherapy drug (sintilimab),…

This program offers early access to the investigational drug selinexor for people with certain advanced cancers, such as multiple myeloma, lymphoma, sarcoma, and others, who have no other treatment options. Patients must not qualify for any ongoing clinical trial and must have ex…

This study tests a new type of radiation called spatially fractionated radiation therapy for people with cervical cancer or pelvic cancer that has come back. It is for patients who cannot get the usual brachytherapy because of unusual anatomy or large tumors. The goal is to see i…

This early-phase trial is testing a new drug called 177Lu-RAD204, which is a radioactive antibody designed to seek out and destroy cancer cells that have a protein called PD-L1 on their surface. The study will involve 30 adults with advanced solid tumors (like lung, breast, or sk…

This early-stage trial is testing a new drug called TORL-1-23 in about 90 people with advanced solid tumors, including ovarian, endometrial, and lung cancers. The drug is an antibody drug conjugate designed to target and kill cancer cells. The main goals are to check safety, find…

This study tests a less invasive weight-loss procedure called endoscopic suture gastroplasty (ESG) in 74 obese women who have had curative treatment for endometrial cancer. The goal is to see if ESG is safe and effective for helping these women lose weight, since obesity raises t…

This early-stage trial tests the safety of combining two drugs, ONC201 and atezolizumab, in 58 women with advanced or recurrent endometrial cancer. The study includes both obese and non-obese participants to see if body weight affects treatment. The goal is to find the best dose …

This study tests a new drug called TCC1727 combined with other medicines (benmelstobart, olaparib, or topotecan) in people with advanced solid tumors, including lung, stomach, endometrial cancer, and melanoma. The goal is to find the safest dose and see if the combination helps s…

This study tests whether adding a behavioral weight loss program to standard hormone therapy helps premenopausal women with obesity and early endometrial cancer or precancer keep their uterus and fertility. About 96 women will receive either the weight loss program plus hormone t…

This study tests whether taking a daily targeted therapy pill (olaparib) for one year after standard chemoradiation can prevent endometrial cancer from coming back in patients with a specific genetic change (p53 abnormal). About 554 participants will be randomly assigned to recei…

This Phase II study tests a combination of three drugs—BL-B01D1, pembrolizumab, and possibly bevacizumab—in people whose cervical or endometrial cancer has come back or spread. The goal is to see if the combo shrinks tumors and to find the best dose. About 96 adults aged 18–75 wi…

This study tests a modified virus (KD01) that targets and kills cancer cells, given alone or with an immunotherapy drug (AK104). It includes 97 women with cervical or endometrial cancer, some of whom have not responded to standard treatments. The goal is to see if the virus is sa…

This early-stage trial is testing an experimental drug called BL0175, a nano-medicine designed to deliver treatment directly into tumors. It is for postmenopausal women with advanced or metastatic hormone-receptor-positive breast, ovarian, or endometrial cancer that has progresse…

This study looks at whether specific diets can help overweight women with endometrial cancer who are receiving fertility-sparing therapy. Participants are randomly assigned to intermittent fasting, a low-energy balanced diet, or routine care. The goal is to see if these diets imp…

This phase 2 study tests whether combining avelumab (an immunotherapy) with M1774 (a targeted drug) can shrink tumors or delay cancer growth in 25 people with ARID1A-mutated endometrial cancer that has returned after prior immunotherapy. Participants receive both drugs intravenou…

This early-stage trial is testing a new drug called DR-0202, a bispecific antibody, in people with advanced solid tumors (such as breast, lung, and pancreatic cancers) that have not responded to at least two prior treatments. The study aims to find a safe dose and see if the drug…

This study tests a new combination of drugs (sapanisertib and serabelisib, together called PIKTOR) plus standard chemotherapy (paclitaxel) in people with advanced or recurrent endometrial cancer that has not been cured by prior treatments. The goal is to see if this combo can shr…

This phase 2 trial is testing whether the immunotherapy drug dostarlimab, given together with standard chemotherapy (carboplatin and paclitaxel), can help Chinese patients with a specific genetic type of advanced or recurrent endometrial cancer. The study will enroll 30 participa…

This study tests an experimental drug, YL205, in 252 people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is given by IV every three weeks. The main goals are to check safety, find the right dose, and see if it helps shrink tumors. This is …

This phase 2 trial tests zanidatamab, a drug that targets cancer cells with a HER2 gene alteration, in 105 adults with advanced lung, endometrial, colorectal, head & neck, or sarcoma cancers. Participants receive the drug every 3 weeks, and doctors monitor tumor shrinkage and sid…

This early-stage trial tests an experimental drug called ADU-1805, alone or combined with the immunotherapy Keytruda, in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety and find the right dose. About 130 pa…

This early-phase trial tests a new drug called MT-4561 in about 27 people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have no standard options left. The main goals are to find a safe dose and see if the drug can shrink tumors. It is a first-in-human s…

This early-phase study tests a new drug called zanzalintinib combined with standard chemotherapy (paclitaxel) in people with recurrent high-grade uterine or endometrial cancer. The main goal is to find the safest and most effective dose of the combination. About 36 participants w…

This early-phase study tests a new treatment called GC203 TIL for people with advanced solid tumors (cancers in organs like the breast, lung, or gut) that have not responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to bet…

This early-phase study tests a new drug called GV20-0251 in people with advanced solid tumors (like liver, lung, or skin cancer) that have stopped responding to standard therapies. The main goal is to check the drug's safety in a small group of 10 patients. It is not a cure, but …

This study is the first to test AVZO-021, an oral drug that blocks a protein called CDK2, in people with advanced solid tumors. The trial will enroll about 430 adults with certain breast, ovarian, or other cancers. The goal is to find safe doses and see if the drug can shrink tum…

This study tests a combination of two drugs, nab-sirolimus and letrozole, in 29 people with advanced or recurrent endometrioid endometrial cancer that cannot be removed by surgery. The goal is to see if the combination shrinks tumors or slows cancer growth. Participants take both…

This study tests a drug called belzutifan in people with a rare, hard-to-treat type of gynecologic cancer called clear cell carcinoma. The goal is to see if the drug can shrink tumors or stop them from growing. About 32 participants will receive the drug, and researchers will mon…

This study tests a new daily pill, VLS-1488, for people with advanced solid tumors that have not responded to other treatments. About 200 participants with specific cancers like ovarian, lung, or breast cancer will receive the drug to see if it is safe and shrinks tumors. The goa…

This phase 2 trial tests a personalized cell therapy called lifileucel (TIL) in 60 people with advanced endometrial cancer that has been treated before. Doctors take a sample of the patient's tumor, grow immune cells from it in a lab, and then infuse them back after a short cours…

This study is testing a new robotic system, called da Vinci SP, for surgery to stage and treat endometrial cancer. The surgery involves removing the uterus, ovaries, and fallopian tubes, and checking nearby lymph nodes. Researchers want to see if this robot is safe and effective …

This study compares two types of minimally invasive surgery for early-stage endometrial cancer: robot-assisted laparoscopy and conventional laparoscopy. About 1,680 patients will be randomly assigned to one of the two procedures. The goal is to see which approach offers better va…

This early-stage trial is testing an experimental drug called LB1410, a bispecific antibody designed to block two immune checkpoints (PD-1 and TIM-3) and help the immune system fight cancer. It involves 100 adults with advanced solid tumors or lymphoma who have exhausted standard…

This study tests whether a calorie-controlled diet can improve tumor outcomes and metabolic health in overweight or obese women with endometrial cancer who are undergoing fertility-sparing treatment. 240 participants will be randomly assigned to either a structured weight managem…

This study is collecting vaginal fluid samples from 4,200 people to develop a new test for endometrial cancer. Participants include those with abnormal uterine bleeding or a recent endometrial cancer diagnosis. The goal is to find biomarkers that could lead to a simple, non-invas…

This study explores whether a tampon can collect DNA samples from the vagina to detect endometrial and ovarian cancer early. Researchers will compare tampon samples with tissue and blood from 1,500 women undergoing surgery. The goal is to develop a simple, non-invasive screening …

This study looks at whether a menstrual cup can collect enough uterine tissue to screen for endometrial cancer, especially in women with Lynch syndrome who are at higher risk. About 25 participants will use a menstrual cup at home and also have a standard biopsy, then compare the…

This study is testing a new type of PET scan that uses special radioactive tracers to find and map solid tumors in the body. The tracers target a protein called Trop2, which is often found on cancer cells. Researchers will enroll 400 people with various cancers (including bladder…

This study looks at whether DNA markers in urine, vaginal, and cervical samples can better identify endometrial cancer risk in women with postmenopausal bleeding. About 600 participants will provide samples and undergo standard ultrasound. The goal is to see if these non-invasive…

This study is testing a new imaging agent called 18F-T2, which is designed to highlight tumors that produce a protein called CAIX. About 200 adults with various cancers (like kidney, lung, or breast cancer) will receive an injection of 18F-T2 and then undergo a PET/CT scan. The g…

This study aims to develop a screening test that uses a vaginal swab and blood sample to find DNA markers for endometrial, ovarian, and cervical cancers. Researchers at Mayo Clinic will enroll over 3,000 women to see if the test can accurately detect these cancers at an early sta…

This study aims to find a gentler way to detect uterine cancer early in people with abnormal bleeding. Instead of relying only on a biopsy, researchers will use a health questionnaire and a self-collected vaginal swab to look for cancer-related genetic changes and microbiome patt…

This study looks at whether the things people buy at stores—like pain relievers or digestive aids—could be early warning signs of cancer. Researchers will compare the shopping habits of 2900 people, some diagnosed with cancer and some not, to see if certain purchases happen more …

This study is testing a new, non-invasive way to detect endometrial cancer using DNA methylation testing on urine and vaginal samples collected by patients themselves. Researchers will compare samples from 120 women—half with endometrial cancer and half healthy—to see if the test…

This study is testing a blood test that looks for DNA signals from 20 different cancers, including lung, breast, and colon cancer. Researchers will see if the test can find cancer early, detect any cancer left after treatment, and catch a relapse before it shows up on scans. The …

This early-stage study tests whether a dye called CYTALUX (pafolacianine) can make endometrial cancer cells glow under a special camera during surgery. The goal is to help surgeons find and remove all cancer. Ten adults with endometrial cancer who are already scheduled for surger…

This study compares two methods—OSNA and ultrastaging—for finding cancer in lymph nodes removed during surgery for early-stage endometrial cancer. About 1,900 women will be randomly assigned to one of the two detection techniques. The goal is to see which method finds more cancer…

This study tests a new device called DOvEEgene Fleur for collecting cells from inside the uterus to detect cancers of the endometrium, tubes, and ovaries. The goal is to see if it is less painful and easier to use than the current brush, while still collecting enough cells for ac…

This study aims to create an educational tool that helps women and their doctors make informed choices about using a levonorgestrel-releasing intrauterine system (LNG-IUS) to prevent endometrial cancer. Researchers will survey 270 women, both with and without a history of the dis…

This study offers free genetic testing to 5,000 women, trans men, and non-binary people with female reproductive organs, regardless of family history. The goal is to find hidden gene changes that raise the risk of breast, ovarian, bowel, and womb cancers. Participants use a smart…

This study is testing a precise type of radiation (proton beam) given to the pelvis after surgery for cervical, uterine, or endometrial cancer. The goal is to see if it causes fewer bowel side effects than standard radiation. About 25 adults who need pelvic radiation after surger…

This study tests if a newer, shorter course of radiation therapy (MH-ART) is as good as the standard longer course (CF-IMRT) for women who have had surgery for cervical or endometrial cancer. The goal is to see if the new approach causes fewer side effects and improves quality of…

This study compares two types of radiation therapy—proton therapy and standard intensity-modulated radiation therapy (IMRT)—given after surgery for cervical or endometrial cancer. The goal is to see if proton therapy causes fewer bowel side effects. About 120 women will fill out …

This study compares two standard radiation methods—proton therapy and photon therapy—for women with newly diagnosed cervical or endometrial cancer. The goal is to see which approach causes fewer stomach and bowel side effects. About 116 participants will be randomly assigned to o…

This phase 2 trial tests whether guarana, a natural supplement from the Amazon, can reduce fatigue in 86 people with neuroendocrine tumors or gynecologic cancers. Participants take either guarana or a placebo daily for up to 42 days, and researchers measure changes in fatigue usi…

This study tests whether cancer patients can complete a supervised exercise program from home using video calls. The program includes resistance training with dumbbells and aerobic exercise. Researchers want to see if this approach is practical and helps patients maintain functio…

This study tests a new way to deliver radiation therapy for endometrial cancer using daily MRI scans to guide the beam. The goal is to give a higher dose of radiation to the tumor while sparing nearby organs like the bowel and bladder. Thirty participants will receive 15 sessions…

This study tests whether using cold wraps plus compression (cryocompression) on hands and feet during chemotherapy can reduce nerve damage (peripheral neuropathy) in people with gynecologic cancer. About 190 participants will be randomly assigned to receive either cryocompression…

This study tests a personalized physical activity program for women over 60 with gynecologic cancers who are receiving chemotherapy or other systemic treatments. The program includes a wearable activity tracker and a smartphone app, plus optional features like an exercise partner…

This study tests whether a high-protein nutrition plan combined with resistance exercises, started weeks before surgery and continued for 24 weeks after, can help older adults with cancer preserve their physical function. The trial enrolls Veterans aged 55 and older with certain …

This study is testing whether a shorter course of pelvic radiation after surgery works as well as the standard longer schedule for people with cervical or endometrial cancer. The shorter schedule means fewer hospital visits and less time in treatment. About 120 participants will …

This study tests whether Reiki therapy can reduce anxiety and pain in people receiving brachytherapy for gynecologic cancers. 70 participants will either receive Reiki or standard care during their treatment. Researchers will measure changes in anxiety, pain, and mood using quest…

This study tests whether using a virtual reality headset during brachytherapy (a type of internal radiation for cervical cancer) can reduce pain, anxiety, and the need for medication. Twenty women will try VR during one treatment session and compare it to a session without VR. Th…

This study looks at two standard radiation treatments for early-stage endometrial cancer to see which one causes less sexual dysfunction. About 258 women who have had surgery for early-stage endometrial cancer will receive either 3 or 6 sessions of vaginal brachytherapy. The main…

This study tests whether weight loss drugs like tirzepatide and semaglutide are practical and safe for endometrial cancer patients who are overweight, obese, or have diabetes and are undergoing chemotherapy. About 36 participants will take weekly doses for 24 weeks. Researchers w…

This study looks at whether alternate day fasting (eating very little every other day) before chemotherapy can help reduce side effects and improve quality of life for women with ovarian, endometrial, or uterine cancer. About 30 women who have had surgery and are about to start c…

This study tests whether a program of exercise, nutrition advice, and mental support before surgery helps gynecological cancer patients recover faster and feel better. About 64 women with ovarian or endometrial cancer will be randomly assigned to either standard care or the preha…

This study tests whether a single dose of NPX-5 (a psilocybin drug) combined with talk therapy can reduce severe anxiety in people who have trouble adjusting to a cancer diagnosis. About 87 adults aged 18–80 with moderate-to-severe anxiety will receive one of three doses (25 mg, …

This study explores whether acupuncture can reduce nerve pain and numbness caused by chemotherapy in people with gynecologic, urologic, or rectal cancers. About 75 participants will be randomly assigned to receive real acupuncture, sham acupuncture, or usual care for 6 weeks. The…

This study tests whether a 16-week, virtually supervised exercise program can help patients with ovarian or endometrial cancer maintain leg function and reduce chemotherapy-induced nerve damage. Thirty patients who have had surgery and are starting first-line chemo will be assign…

This study tests whether a daily probiotic pill (Pendulum Glucose Control) can safely reduce stomach and bowel problems in people receiving radiation for cancers of the pelvis, such as prostate, gynecologic, or lower GI cancers. About 20 adults will take the probiotic during thei…

This study tests whether a personalized physical activity program using a wearable device (like a Fitbit) can help people with ovarian or endometrial cancer exercise more and improve their quality of life. About 120 participants will either receive tailored activity goals and fee…

This study tests whether a pre-surgery program of exercise and a dietary supplement called Ocoxin can improve recovery for 100 women undergoing surgery for gynecologic cancers like endometrial, ovarian, or cervical cancer. Participants will follow an enhanced recovery protocol (E…

This study looks at whether using the Headspace mindfulness app before surgery or chemoradiation can help people with endometrial or cervical cancer use fewer opioid painkillers. About 120 participants will be randomly assigned to use the app or not. The goal is to see if mindful…

This study talks to women with and without endometrial cancer to learn what they know about risk factors and prevention options. Researchers hope to create a tool that helps women make informed decisions. About 45 women will take part at MD Anderson Cancer Center.

This observational study in Vietnam looks at archived tumor samples from patients with several solid cancers, including liver, colorectal, gastric, breast, lung, endometrial, melanoma, and pancreatic cancer. Researchers will measure the presence of two proteins, ENPP1/cGAS and FA…

This study looks at the genetic makeup of advanced endometrial cancer in 500 women in Russia. Researchers will test tumor samples for specific gene changes to see how common they are and what treatments patients receive. The goal is to gather information, not to test a new treatm…

This study will test tumor samples from 350 adults with gynecological cancers (endometrial, ovarian, cervical, vulvar, and vaginal) to see how often they have high levels of the HER2 protein. Researchers will use two standard lab tests to measure HER2. The goal is to learn how co…

This study explores whether people with Lynch syndrome can use a self-collected vaginal swab at home to detect early signs of uterine cancer. Researchers will enroll 30 participants who will collect samples and answer surveys. The main goal is to see if this approach is practical…

This study looks at the best times to send messages that encourage physical activity to older cancer survivors (65+) who have chronic pain. About 50 participants will wear an activity tracker and rate their pain four times a day using a smartphone app. The goal is to see if certa…

This study looks at tumor samples from 2,100 Chinese patients with lung, gynecologic, bile duct, or bladder cancers. Researchers will compare different HER2 testing methods to see how well they agree with each other. The goal is to improve the accuracy of HER2 testing, which help…

This study is observing about 1,715 people with early-stage endometrial cancer to see how often the cancer comes back and how often lymphedema (swelling) happens after standard treatment. Participants will have regular check-ups for 36 months. The goal is to gather real-world dat…

This study collects tissue samples, medical data, and family histories from over 1,100 people being screened for colorectal or endometrial cancer. Researchers hope to discover new genes and mechanisms that increase cancer risk, especially in hereditary cancer syndromes. The goal …

This study looks at whether older adults with gynecologic cancer are willing to complete physical and cognitive tests before and after treatment. Researchers will also take small muscle and blood samples to study how cell energy relates to resilience. The goal is to see if this k…

This study is testing a computer model called ENDORISK that helps doctors predict whether endometrial cancer has spread to lymph nodes. About 735 patients with early-stage endometrial cancer will use the model to guide decisions about lymph node surgery. The goal is to see if the…

This study looks at whether giving chemotherapy before surgery helps older adults (over 55) with advanced ovarian or endometrial cancer become fitter for their operation. Researchers will measure changes in frailty using a special score from medical records. The goal is to see if…

This study looks at whether it is safe for women with endometrial cancer to fast overnight before their surgery. Many women with this cancer have high blood sugar and inflammation, which may help the cancer grow. The study will check if fasting is doable and liked by patients, an…

This study investigates why some advanced or recurrent endometrial cancers respond to immunotherapy while others do not. Researchers will collect tumor samples from 510 patients before they start immunotherapy and use lab-grown tumor models to study molecular and genetic features…

This study is for young adults (ages 21-45) who had certain cancers as teens or young adults. Researchers are adapting a program that helps survivors manage their health after cancer treatment. The goal is to see if this program improves survivors' confidence and ability to handl…

This study is building a huge registry of information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. Researchers will use this resource to study what causes cancer and how to better prevent, detect, and treat it. The re…

This study is collecting live tumor samples from 2,000 cancer patients undergoing standard biopsies. Researchers will analyze these samples to understand how tumors respond to immunotherapy drugs outside the body. The goal is to develop a method to predict which patients will res…

This pilot study is testing whether a 7-day integrative oncology retreat called 'Via Shalva' is practical and helpful for women who have finished primary treatment for breast or gynecologic cancer. Thirty participants will either attend the retreat or receive usual follow-up care…

This observational study is looking at 350 women with early-stage endometrial cancer to see if doctors can better predict who really needs lymph node removal during surgery. Participants receive standard care and are followed for three years. The goal is to find out if some patie…

This study collects tumor and blood samples from 3,300 people at high genetic risk for breast, ovarian, and related cancers. Researchers want to learn how these cancers develop and how well treatments work. Participants include those with BRCA1/2 or other gene mutations, or a str…

This study aims to gather and analyze detailed medical information from 10,000 people diagnosed with endometrial cancer in Italy. Researchers will look at how the cancer's molecular and immune features affect how long patients stay free of the disease and how long they live overa…

This study surveys about 264 Italian hospitals that treat endometrial cancer to find out how often they use POLE testing. POLE testing helps doctors know which patients have a very low risk of cancer returning and may not need extra treatment. The goal is to understand current pr…

This study follows 200 women with gynecologic cancer and their partners to see how sexual function changes over time. Researchers use questionnaires at diagnosis, 6 months, and 12 months after treatment. The goal is to understand when sexual counseling might be most helpful, with…

This study looks at the genetics of high-risk endometrial cancer to find out why it sometimes returns after treatment. About 100 adults having surgery at Mayo Clinic will provide tissue and blood samples. Researchers will analyze these samples to build a databank for future studi…

This study will analyze the genes of 25,000 adults who have cancer or are at risk for it. Researchers will use advanced testing to find genetic changes linked to cancer and track health records over time. The goal is to learn more about cancer biology and discover new ways to per…

This study looks at women who had radiation therapy for cervical or endometrial cancer to see how often they experience long-term side effects in the bowel or bladder. Researchers will review medical records of 300 patients treated at Tata Memorial Hospital. The goal is to unders…

This study is testing whether a web and mobile phone program can help Hispanic women who have had breast, uterine, or ovarian cancer, along with their adult daughters, eat better and be more active. The program includes 8 online modules. The main goal is to see if the program is …

This study looks at whether changes in a blood marker called CRP can help predict how well immunotherapy works in women with advanced gynecologic cancers (cervical, endometrial, ovarian, or vulvar). Researchers will track CRP levels in 120 women receiving immunotherapy plus chemo…

This study tests whether 3D-printed custom applicators can deliver radiation more precisely than standard cylinder applicators for gynecologic cancers like endometrial, vaginal, and vulvar cancer. Ten participants will receive brachytherapy with a personalized 3D-printed mold. Th…

This study looks at how the dose and storage conditions of a dye called indocyanine green (ICG) affect its ability to find sentinel lymph nodes during surgery for cervical, endometrial, and vulvar cancers. Researchers will enroll 30 patients to see which approach works best and s…

This study is a large German registry that will follow nearly 2,000 people with advanced ovarian or endometrial cancer. Researchers will collect information on the treatments patients actually receive, how their disease responds, and their quality of life. The goal is to understa…

This study collects blood and leftover tissue samples from 9,600 people with various cancers, including breast, lung, and pancreatic cancer. Researchers will use these samples to improve tests that look for cancer DNA in the blood. The goal is to better detect if cancer returns o…

This study looks at whether a special hospital visit with a team of experts can help women who finished treatment for ovarian or endometrial cancer get more of the supportive care they need. About 268 women in remission will be split into groups: some get the extra hospital asses…

This study tests whether a special ultrasound can measure changes in vaginal tissue caused by radiation therapy for endometrial cancer. Ten participants will have ultrasound scans before and after treatment to see if the method works. The goal is to better understand and monitor …

This study is testing whether tumor tissue from endometrial cancer patients can be successfully turned into organoids (tiny lab-grown models) after being transported from other hospitals. About 20 adults with endometrial cancer will provide a sample during their standard surgery.…

This study compares two approaches after robotic hysterectomy: going home the same day versus staying overnight in the hospital. Researchers will track quality of life and complications over 30 days in 300 patients with benign conditions or endometrial cancer. The goal is to see …

This study looks at 625 women with endometrial cancer to compare two surgical methods for checking lymph nodes: selective staging versus removing all nodes. The goal is to see which approach leads to better cancer-free survival. Participants will be followed over time to track re…

This pilot study looks at whether showing educational videos about genetic testing can increase the number of patients with ovarian or endometrial cancer who get tested. About 30 participants will watch a short video relevant to their cancer type and then fill out a satisfaction …

This study is testing whether an artificial intelligence (AI) tool can help match cancer patients with the right clinical trials. Researchers will enroll up to 50,000 people with various cancers to see if the AI improves trial enrollment rates and patient outcomes. The goal is to…

This study is looking at whether using a device called a uterine manipulator during minimally invasive surgery for early stage endometrial cancer causes cancer cells to spread into the abdominal fluid. About 278 women will be randomly assigned to have surgery with or without the …